National Research Co. (NASDAQ:NRC) Short Interest Down 14.7% in May

National Research Co. (NASDAQ:NRC - Get Free Report) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 344,700 shares, a decline of 14.7% from the April 30th total of 404,200 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average trading volume of 98,900 shares, the short-interest ratio is presently 3.5 days.

Insider Buying and Selling at National Research

In other news, major shareholder Patrick E. Beans bought 2,500 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average price of $13.59 per share, with a total value of $33,975.00. Following the completion of the acquisition, the insider now directly owns 35,003 shares in the company, valued at approximately $475,690.77. This trade represents a 7.69% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.10% of the stock is currently owned by insiders.

Institutional Trading of National Research

Hedge funds and other institutional investors have recently modified their holdings of the stock. ExodusPoint Capital Management LP lifted its position in National Research by 3.4% in the 4th quarter. ExodusPoint Capital Management LP now owns 21,035 shares of the company's stock valued at $371,000 after acquiring an additional 694 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in National Research by 5.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,250 shares of the company's stock valued at $252,000 after acquiring an additional 752 shares in the last quarter. Aviso Financial Inc. lifted its position in National Research by 37.2% in the 1st quarter. Aviso Financial Inc. now owns 3,076 shares of the company's stock valued at $39,000 after acquiring an additional 834 shares in the last quarter. Jane Street Group LLC lifted its position in National Research by 8.6% in the 4th quarter. Jane Street Group LLC now owns 10,605 shares of the company's stock valued at $187,000 after acquiring an additional 840 shares in the last quarter. Finally, Semanteon Capital Management LP lifted its position in National Research by 9.9% in the 4th quarter. Semanteon Capital Management LP now owns 10,281 shares of the company's stock valued at $181,000 after acquiring an additional 929 shares in the last quarter. Institutional investors and hedge funds own 47.26% of the company's stock.

National Research Stock Up 4.5%

Shares of National Research stock traded up $0.65 on Friday, hitting $15.02. 108,126 shares of the company traded hands, compared to its average volume of 96,299. The company has a 50-day moving average price of $12.52 and a 200 day moving average price of $15.37. The company has a quick ratio of 0.47, a current ratio of 0.47 and a debt-to-equity ratio of 1.30. National Research has a 12-month low of $9.76 and a 12-month high of $27.07. The company has a market cap of $342.23 million, a PE ratio of 14.30 and a beta of 0.34.

National Research (NASDAQ:NRC - Get Free Report) last released its earnings results on Monday, April 28th. The company reported $0.25 earnings per share for the quarter. National Research had a net margin of 17.32% and a return on equity of 66.52%. The firm had revenue of $33.55 million during the quarter.

National Research Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 3.20%. The ex-dividend date is Friday, June 27th. National Research's payout ratio is 46.60%.

About National Research

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.